DEA Rejects Proposal to Change Classification of Marijuana

by Brian Williams
PharmD, Research Fellow

Marijuana remains a Schedule I drug In a letter from Acting Administrator Chuck Rosenberg, the U.S. Drug Enforcement Administration (DEA) has rejected a proposal to change the federal classification of marijuana from a Schedule I to a Schedule II drug. By keeping it in Schedule I, the DEA is maintaining that marijuana has no currently …

Drug of the Month – Vivlodex™ (meloxicam)

by Alan Rook, PharmD, Clinical Pharmacist
Krupa Patel, PharmD candidate

What is Vivlodex? Vivlodex (meloxicam) is a single-source brand medication that was FDA approved in October 2015 for the management of osteoarthritis (OA) pain. Vivlodex is a nonsteroidal anti-inflammatory drug (NSAID) that prevents the synthesis of prostaglandins in body tissue by inhibiting COX-1 and COX-2. Current Official Disability Guidelines (ODG) suggest that the use of …

Journey to a Guideline: The Process and Overview of the Long-Awaited CDC Guideline on Opioid Prescribing for Primary Care

by Phil Walls, RPh, Chief Clinical Officer
Steven Stanos, DO

Will the New CDC Guideline Have an Impact on Opioid Prescribing? Last week, myMatrixx released a blog providing a summary of key concepts gleaned from the CDC Guideline for Prescribing Opioids for Chronic Pain.  Since then, we have received numerous questions from clients and industry insiders regarding whether or not this latest set of guidelines …

Drug of the Month: 4 Key Things to Know About Lyrica®

by Alan Rook, PharmaD, Clinical Pharmacist
Ashton Hamilton, PharmD candidate

1. What is Lyrica? Lyrica® (pregabalin) is FDA approved for fibromyalgia, diabetic peripheral neuropathic pain, neuropathic pain associated with spinal cord injury, partial-onset seizures (adjunctive therapy), and post-herpetic neuralgia. Lyrica is used off-label for general neuropathic pain, episodic migraine prevention, hot flashes, and restless leg syndrome. Current Official Disability Guidelines (ODG) suggest Lyrica and gabapentin …

Drug of the Month: 4 Things You Should Know About Amitiza

by Alan Rook, PharmaD, Clinical Pharmacist
Ashton Hamilton, PharmD candidate

1. What is Amitiza®? Amitiza (lubiprostone), manufactured by Takeda Pharmaceuticals Inc., is FDA approved for opioid-induced constipation in patients with chronic non-cancer related pain. It works by activating chloride channels in the intestines—which promotes fluid secretion in addition to assisting with passing of the stool. 2. How is Amitiza available? Amitiza is available as an …

States Continue to Take a Stand Against the Prescription Opioid Epidemic

by Tammy Odierna
Regulatory Data Analyst

Earlier this month, Connecticut Governor Dannel Malloy hosted a bill signing ceremony to celebrate passage of PDMP legislation: CT HB 6856. Governor Malloy championed the bill as “common sense legislation” that “will help save lives and address a pressing public health need.” Governor Malloy said, “We have to treat addiction like a public health issue …

What Does the New NSAID Label Warning Mean for Workers’ Comp?

by Sam Aminov
PharmD, MBA

FDA Strengthens Label Warning on NSAIDs In a recent Drug Safety Communication, the U.S. Food and Drug Administration (FDA) strengthened an existing label warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) increase the chance of a heart attack or stroke[i]. The cardiovascular risks of NSAIDs were first described back in 2005. A comprehensive review of new …

Drug of the month for June: 5 Points to Remember When Considering Amrix

by Alan Rook
PharmD, Clinical Pharmacist

This is the third post for our “Drug of the Month” blog. The medication that we’re highlighting is Amrix® (cyclobenzaprine extended-release). This drug was chosen based on the number of inquiries that our clinical department receives regarding this medication. One of the inquiries we receive is: is there a therapeutic alternative to Amrix® that might …

“Operation Pilluted” Largest DEA Prescription Drug Operation Ever

by Alan Rook
PharmD, Clinical Pharmacist

The DEA (Drug Enforcement Administration) and federal prosecutors have announced the conclusion of a 15-month operation dubbed “Operation Pilluted.” The operation was an unprecedented law enforcement effort to reverse the effects of the trafficking and abuse of pharmaceuticals, and the operation resulted in the arrest of 280 people, including 22 doctors and pharmacists across four …